Sign In
Buy LLY
$1,185.71
-6.23 (-0.523%)
At Close: Aug 07, 2026
EIi Lilly's weight-loss drug is 'much better' than others on the market, says Wells Fargo's Bansal
06:32pm, Monday, 01'st May 2023
Mohit Bansal, Wells Fargo managing director, joins 'Fast Money' to discuss Eli Lilly's recent stock performance as demand for its weight-loss drugs climb.
V&M Breakouts: Top Long-Term Growth And Dividend Stocks For May 2023
04:51pm, Monday, 01'st May 2023
The May 2022 total return portfolio for 1-year is up +17.09%, and the May 2021 2-year portfolio is up 21.33%, not adjusted for greater than 2%+ dividends. The first May 2020 portfolio had +66.98% 2-ye
Alzheimer's patients may wait years to get treated with new drugs, putting them at risk of more severe disease
09:00am, Sunday, 30'th Apr 2023
Patients could face wait times ranging from 18 months to four years or more to get diagnosed and then treated for Alzheimer's disease.
Why Eli Lilly Stock Was a Winner Today
06:11pm, Friday, 28'th Apr 2023
The pharmaceutical company benefitted from a clutch of analyst price-target raises. These followed Lilly's well-received earnings report.
Weight loss drug market is just beginning to take off, says Mizuho's Jared Holz
02:33pm, Friday, 28'th Apr 2023
Jared Holz, Mizuho healthcare equity strategist, joins 'The Exchange' to discuss new weight loss drugs coming to market, forecasts for market expansion in weight loss drugs, and key players in the wei
5 Brand-Name Safe Stocks I Wouldn't Touch With a 10-Foot Pole Right Now
05:21am, Friday, 28'th Apr 2023
The Federal Reserve is now forecasting a mild recession for later this year. When uncertainty picks up, investors typically flock to safe stocks.
Is Eli Lilly Stock a No-Brainer Buy After Mounjaro's Latest Big Win?
05:49pm, Thursday, 27'th Apr 2023
Lilly is now racing toward likely approval for Mounjaro in treating obesity after positive late-stage results. The bigger picture for the company also looks good overall.
Analyst discusses weight loss drugs and why he's bullish on Eli Lilly
05:39pm, Thursday, 27'th Apr 2023
Evan Seigerman, BMO Capital Markets Managing Director of BioPharma Equity Research, joins Yahoo Finance Live to discuss why investors are becoming bullish on weight-loss drug opportunities and the out
Eli Lilly (LLY) Q1 Earnings Miss, Sales Beat, '23 View Raised
03:57pm, Thursday, 27'th Apr 2023
Eli Lilly (LLY) reports mixed results for the first quarter of 2023, missing estimates for earnings while beating the same for revenues. Management raises the 2023 outlook.
Eli Lilly stock rises after 1Q revenue beat and pipeline momentum from diabetes and weight loss drug Tirzepatide
11:31am, Thursday, 27'th Apr 2023
Eli Lilly & Co stock climbed after the drug maker reported first-quarter earnings showing a revenue beat and raised its full-year guidance. For the quarter ended March 31, 2023, the Indianapolis-based
Why Are Stocks Up Today?
11:19am, Thursday, 27'th Apr 2023
Investors wondering why stocks are up today have a couple of pieces of news worth catching up on. First off, stocks are up today thanks to several large corporations releasing earnings reports.
Obesity Drug Hype Outweighs Profit Miss at Eli Lilly
11:12am, Thursday, 27'th Apr 2023
Mounjaro excitement more than makes up for company's first quarter results.
LLY Stock Alert: Mounjaro Takes Eli Lilly to the Next Level
10:13am, Thursday, 27'th Apr 2023
Eli Lilly (NYSE: LLY ) stock is climbing higher on Thursday thanks to a boost from Mounjaro during its earnings report for the first quarter of 2023. According to the company, diabetes drug Mounjaro s
Eli Lilly Pushes For Fast-Track Approval Of Mounjaro As Weight-Loss Drug
10:02am, Thursday, 27'th Apr 2023
Late-stage trials suggest Lilly's tirzepatide, sold under Mounjaro, could be a more effective obesity drug that Ozempic or Wegovy, and the company expects a regulatory decision by the end of the year.
Is Eli Lilly Stock a Strong Buy After Q1 Earnings?
09:25am, Thursday, 27'th Apr 2023
Shares have been on the volatile side this year due to a slew of headwinds. Over the long term, these headwinds will likely fade due to the growth potential of its rapidly emerging flagship drug, Moun
